Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.5% year on year to $711.1 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.
Is now the time to buy RVTY? Find out in our full research report (it’s free for active Edge members).
Revvity (RVTY) Q2 CY2026 Highlights:
- Revenue: $711.1 million vs analyst estimates of $707.2 million (4.5% year-on-year growth, 0.6% beat)
- Adjusted EPS: $1.41 vs analyst estimates of $1.22 (15.9% beat)
- The company slightly lifted its revenue guidance for the full year to $2.85 billion at the midpoint from $2.83 billion
- Management raised its full-year Adjusted EPS guidance to $5.35 at the midpoint, a 1.9% increase
- Operating Margin: 12.6%, in line with the same quarter last year
- Organic Revenue rose 3% year on year (beat)
- Market Capitalization: $12.43 billion
StockStory’s Take
Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environment," with notable improvement in pharma and biotech end markets, and emphasized accelerating demand for tools that enable AI-driven science, particularly high-content screening instruments like the Opera Phenix OptIQ. He noted that these trends contributed to an elevated instrument backlog exiting the quarter, indicating strong underlying demand despite some delivery timing effects.
Looking forward, Revvity’s updated guidance is underpinned by optimism around improving end-market conditions, especially as AI adoption in drug discovery gains traction and Diagnostics momentum continues. Management expects higher organic growth for the full year, driven by increased instrument and reagent demand, as well as software recovery in the second half. Singh described the company as "extremely well positioned to deliver over the remainder of the year, while capitalizing on the new opportunities presenting themselves as preclinical science is redefined in the new AI world." The company’s strategic reinvestments in innovation, supply chain, and operational efficiency are anticipated to support margin stability and position Revvity to capture the evolving opportunities in AI-enabled workflows.
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to sustained Diagnostics growth, accelerating AI-driven demand in Life Sciences, and a strategic shift away from challenging markets like China immunodiagnostics.
- Diagnostics momentum: The Diagnostics segment grew organically by 11%, with particularly strong results in reproductive health and immunodiagnostics outside China. Management highlighted ongoing strength in newborn screening and menu expansion in new markets, which contributed to double-digit growth even amid declining birth rates.
- AI-driven demand surge: Revvity saw a marked increase in orders tied to AI-enabled drug discovery, including from non-traditional customers building new data generation platforms. CEO Prahlad Singh emphasized that "orders specific from AI customers who are building out these massive data sets" have become a notable trend, resulting in a higher-than-normal instrument backlog.
- High-content screening acceleration: The Opera Phenix OptIQ instrument, introduced recently, experienced double-digit growth with order velocity outpacing near-term production capacity. Management noted that this not only benefits instrument revenue but is expected to drive future reagent demand as customers expand lab capacity.
- Software segment transition: Signals software revenue declined due to tough year-over-year comparisons and contract timing, but management expects a return to double-digit growth in the second half, supported by product launches like Signals AI and integration with leading AI models (such as Anthropic’s Claude).
- Strategic portfolio actions: Revvity signed a definitive agreement to divest its China immunodiagnostics business, citing challenging market conditions. The company also completed the integration of ACD/Labs and is using proceeds from one-time tariff refunds to reinvest in operational efficiency, capacity expansion, and key product innovation.
Drivers of Future Performance
Revvity’s outlook is shaped by expanding AI-related demand, continued Diagnostics strength, and reinvestment in growth initiatives, while management remains mindful of execution risks and market normalization.
- AI adoption and instrument pull-through: Management expects AI-driven demand for high-content screening instruments and Lab-in-the-Loop workflows to continue building, with reagent sales following as installed capacity grows. Singh indicated that the company is "at the very early innings of this growth trajectory," and incremental demand from new AI-focused customers could further bolster results as the trend expands beyond traditional pharma and biotech.
- Diagnostics resilience and expansion: The Diagnostics segment is forecast to maintain high-single-digit growth, supported by ongoing adoption in reproductive health and newborn screening, geographic expansion, and menu enhancements. However, management cautioned that growth in reproductive health may moderate in the second half due to contract timing and instrument placement cycles.
- Execution on operational initiatives: Revvity is channeling half of its one-time tariff refunds into strategic investments, including manufacturing capacity expansion and software integration. The remainder supports margin stability. Management underscored that further upside depends on continued improvement in end-market conditions, particularly in pharma and biotech, which is not fully embedded in current guidance.
Catalysts in Upcoming Quarters
In coming quarters, our team will be monitoring (1) the pace at which AI-driven demand translates into actual instrument and reagent revenue, (2) the timing and magnitude of Signals software recovery and customer adoption of new AI-enabled features, and (3) ongoing momentum in Diagnostics, particularly in reproductive health and newborn screening. Progress on manufacturing capacity expansion and the successful integration of recent acquisitions will also be important indicators of sustained operational execution.
Revvity currently trades at $111.17, down from $115.22 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.